Cancer Prevention & Control (CPC)

Select Recent Accomplishments

This is an accordion element with a series of buttons that open and close related content panels.

Promising Chemopreventive Targets and Agents

Developing promising chemopreventative targets and agents requires both preclinical discovery and clinical application. CPC members have made substantive progress in each aspect of this process.

Preclinical Discovery

  • Mukhtar, and Khan have observed that transcription/translation regulatory Y-box binding protein-1 (YB-1) expression is increased with carcinoma progression and inversely proportional to E-cadherin expression.
  • Matkowskyj, Deming (DT), and Halberg (GEM) examined th role and “targetability” of PIK3CA mutations in colon carcinogenesis via a novel transgenic model. This research demonstrated first time evidence that AKR1B10 is a unique biomarker involved in hepatocellular carcinogenesis via modulation of proliferation and cell apoptosis and thus a potential promising biomarker for blocking carcinogenesis

Clinical Application

  • Bailey, Downs, Kim, and Mukhtar led a UWCCC consortium Phase 2 Trial of polyphenon E or placebo administered to participants with bladder neoplasia undergoing resection. Follow-up studies are under development.
  • Trentham-Dietz, and Gould (GEM) identified a locus, Mcs5a, as strongly associated with breast cancer risk in both rodent models and humans. Gould and Gumperz (VR) determined this locus prevents breast cancer through down regulation of ubiquitin ligase Fbox10 in T lymphocytes.

Tobacco-related Cancer Progress

Tobacco research has long been an area of strength at the UWCCC, as evidenced by national recognition through prestigious awards and leadership on federal committees. Researchers have also been instrumental in developing novel treatments and programs to reduce tobacco usage.

  • Fiore, named a 2014 UW Hilldale Professorship given to faculty members with outstanding research and promise of continued activity.
  • Piper named the 2014 Jarvik-Russel Young Investigator Awardee by the Society for Research on Nicotine and Tobacco for extraordinary contributions to the field.
  • Fiore and Baker received $12 million for a 5-year program project from the NCI titled “Breaking Additiction to Tobacco for Health” or BREATHE. CPC researchers are testing new phased-based smoking cessation treatments for patients that coordinate advanced electronic health record (EHR) systems and advanced treatment procedures

Translating Research to Clinical Application

The CPC Program conducts research across all phases of the cancer trajectory from prevention, screening, and diagnosis to survivorship and end-of-life care. As a result, our research teams are widely multidisciplinary and bridge sciences including engineering, human development and family studies, kinesiology, medicine, nursing, pharmacy, population health, psychiatry, social work, and surgery.  Examples of CPC research include the following.

  • Studies advancing cancer detection and diagnosis, including use of simulation modeling to identify new approaches to breast cancer screening (Alagoz, Burnside, Gangnon, Trentham-Dietz).
  • Evaluation of physical activity interventions to reduce sedentary behavior and improve health in patients during and after cancer treatment (Cadmus-Bertram)
  • Research developing and testing system-level interventions to improve care delivery, coordination, and follow-up during screening and as cancer survivors transition from active treatment to surveillance (Greenberg, Newman, Sesto, Tevaarwerk)
  • Implementation and evaluation of clinical tools and strategies to improve patient-provider communication, enhance shared decision-making, and achieve goal concordant care, especially for those facing difficult treatment choices and end-of-life decisions (Campbell)
  • Studies to identify and improve management of symptoms, facilitate coping, and enhance quality of life among cancer patients and their caregivers (Hutson, Kwekkeboom, Litzelman)